• Recently, Zacks highlighted that agilon health now carries a Momentum Style Score of B and a Zacks Rank of #2 (Buy), supported by upward revisions to earnings estimates for both the current and next fiscal years.
• An interesting angle is that agilon health’s combination of positive earnings estimate revisions, relative outperformance in medical services, and “Fast-Paced Momentum at a Bargain” screening has drawn attention to the stock’s momentum and valuation profile.
• With analyst earnings estimates moving higher, we’ll examine how this improved sentiment could affect agilon health’s existing investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

agilon health Investment Narrative Recap

To own agilon health, you need to believe its value based care model for seniors can translate demographic tailwinds into consistent earnings, despite recent volatility in membership, margins, and payer negotiations. The Zacks momentum upgrade and higher earnings estimates affirm improving sentiment, but they do not remove the near term execution risk around risk adjustment revenue and contract renewals, which still looks like the key swing factor for the stock.

The most relevant recent development is agilon’s raised 2026 revenue guidance to US$5,680 million to US$5,805 million, alongside sharply improved Q1 2026 profitability. This backdrop helps explain why earnings estimates have been revised upward and why momentum screens are picking up the stock, yet it also raises the stakes if cost trends or payer talks in 2026 fail to support that higher bar.

Yet against this improving sentiment, the risk that payer negotiations and contract renewals in 2026 could pressure revenue and margins is something investors should be aware of...

agilon health's narrative projects $7.0 billion revenue and $42.4 million earnings by 2029.

Uncover how agilon health's forecasts yield a $60.36 fair value, a 49% downside to its current price.

Exploring Other Perspectives

While recent momentum and estimate upgrades look encouraging, the most bearish analysts were assuming only 2.1 percent annual revenue growth and no profitability by 2029, which shows how sharply views can differ and why it may be worth exploring several alternative scenarios around agilon’s execution on risk adjustment and payer contracts.

Explore 4 other fair value estimates on agilon health - why the stock might be worth 49% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your agilon health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free agilon health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate agilon health's overall financial health at a glance.

No Opportunity In agilon health?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.